Perceptic
Summary active Updated May 27, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Perceptic is building an end-to-end AI operating system for drug development, spanning drug discovery to clinical trial design 12. The company was founded by a trio of former Palantir executives who helped spearhead that company’s Life Sciences practice; CEO Tilman Flock is a bioscience researcher who spent nearly seven years at Palantir building its commercial AI platform and helping life sciences companies deploy it 1.
Rather than focusing on a single step in drug development as many AI biotech startups have, Perceptic pitches itself as the “connective tissue” between discrete AI tools and the proprietary internal and external data that pharmaceutical companies use to make decisions 1. Its software is already used by multiple top-tier pharmaceutical companies; the company was authorized to disclose Australian biotechnology firm CSL as a customer 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-05-26 | Seed | $12M | Accel | Air Street Capital, Elder Gull 12 |
What Investors Say
No independently sourced investor quotes found at this time.
What Founders Say
No independently sourced founder testimonials found at this time.
Sources
-
“Exclusive: Ex-Palantir AI execs raise $12 million seed round for Perceptic, a startup automating drug discovery,” Fortune, May 26, 2026. https://fortune.com/2026/05/26/exclusive-perceptic-a-startup-automating-drug-discovery-end-to-end-for-big-pharma-emerges-from-stealth-with-12-million-in-seed-funding/↩↩↩↩↩
-
“Introducing Perceptic: the AI operating system for drug development,” Air Street Press, May 26, 2026. https://press.airstreet.com/p/introducing-perceptic↩↩